The clinical studies based on the use of recombinant allergens do not seem to support the hypothesis that they could be of more benefit in respect to traditional immunotherapy products. Considering the huge investments to be made for their development, I don't think that recombinant allergens, at least as native ones, will be used in the future. Mutant recombinant allergens (with reduced IgE-reactivity) could be a potential alternative. They could be safer and more effective because used at higher dosages but it remains to solve the economic impact needed to develop them. Perhaps if some Allergen Producers decided to join their efforts, such products could be a future.

It is not possible to prepare recombinant forms of all clinically relevant allergens now. In addition, if this was possible, the cost of performing clinical trials to demonstrate safety and efficacy would be cost-prohibitive. Recombinant allergens are far away in the horizon.

Late response, but I wanted to let you know that I completely agree with the different critical aspects mentioned by all contributors. Yet another aspect are the seasonal variations in the case of seasonal allergens. In essence, I don't believe that recombinant allergens will be the future gold standard for allergy immunotherapy.

I would like to add one more idea: I think the immunotherapy of the future will be strongly related to the parasites.